$SUPN

Supernus, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company that develops and commercializes products for central nervous system diseases. Its portfolio includes treatments for ADHD, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Commercial products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO and MYOBLOC. Supernus also develops product candidates for neurology and psychiatry, including SPN-817, SPN-820 and SPN-443. Supernus sells products primarily to pharmaceutical wholesalers, specialty pharmacies and distributors, and markets key products through its own U.S. sales forces. It jointly commercializes ZURZUVAE in the U.S. with Biogen, sharing operating profits and losses, while Biogen records product sales. The company also seeks strategic collaborations to commercialize products outside the U.S. Supernus is headquartered in Rockville, Maryland.

AlphAI earnings readthird quarter 2026 and nine months ended September 30, 2026 · OCT 29Supernus Announces Third Quarter 2026 Financial ResultsVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
0
0

No SEC Form 4 filings for $SUPN in the last 30 days.

See all $SUPN insider activity →
High

Bank of America Sees Up to 95% Upside in 2 Stocks

Bank of America analysts see significant upside in Iambic Therapeutics (95%) and Supernus Pharmaceuticals (60%). Iambic's AI-driven cancer treatment IAM1363 showed promising early results, while Supernus's merger with Indivior is expected to drive revenue growth. Both stocks are rated Buy with specific price targets.

Supernus, Inc. (SUPN) Stock Forecasts

Argus raised its target price for Supernus Inc. (SUPN) to $30.00, maintaining a 'Hold' rating. The company has medium ratings for industry, management, safety, financial strength, and growth, with a high value subrating.

Supernus undervalued after Indivior merger, says Bank of America

Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.

SUPN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SUPN (Supernus, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent SUPN coverage spans financial news, mergers & acquisitions and corporate actions.

What's driving SUPN

AlphAI scores every news story that mentions SUPN with an AI model for sentiment and relevance, and aggregates insider trades from Supernus, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SUPN

Score

Bank of America Sees Up to 95% Upside in 2 Stocks

Bank of America analysts see significant upside in Iambic Therapeutics (95%) and Supernus Pharmaceuticals (60%). Iambic's AI-driven cancer treatment IAM1363 showed promising early results, while Supernus's merger with Indivior is expected to drive revenue growth. Both stocks are rated Buy with specific price targets.

Supernus undervalued after Indivior merger, says Bank of America

Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.

Piper Sandler resumes Supernus Pharmaceuticals stock at Overweight

Piper Sandler resumed coverage of Supernus Pharmaceuticals (SUPN) with an Overweight rating and $47 price target. The stock trades at $28.15, with analysts' price targets ranging from $55 to $67. The firm cited strong strategic logic post-merger, with expected 2027 EBITDA over $1B and net debt around $800M. Key products include Sublocade, Qelbree, Zurzuvae, and Onapgo, which should drive 80% of 2027 revenue.

Other. Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. and U.S. Bank Trust Company, National Association…

Supernus, Inc. (INDV) filed an SEC Form 8-K — Other Events. Item 8.01 Other. Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the “Company” or the “Registrant”) and U.S. Bank Trust Company, National Association (the “ Indenture ”), governing the Company's 0.

Related tickers